Zydus receives USFDA approval to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS Read more
Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107, for treating cognitive disorders Read more
Elucidation of part of the mechanism by which Lecanemab slows the progression of Alzheimer’s Read more